Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Additional NTM defence mechanisms include both innate and acquired antibiotic resistance, plus highly efficient efflux pumps that can swiftly remove antibiotics from the bacterial cell [3].

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and ...

TB is treated with multiple medications over a 6-month period, exposing the human organism to substantial weakening.

The RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932. This Joined Undertaking receives support from the European ...

Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary ...

Dr. Wassim Fares, MSc, FCCP, Senior Vice President, Therapeutic Area Head, Orphan Lung Diseases of MannKind will share a presentation and poster for ICoN-1 at The University of Queensland on Friday, ...